Infusion Rate Escalation Study of Rituximab in Patients with CD20+ B-Cell Lymphomas: A Single Institution Analysis in Japan

Background. To determine the maximum tolerable infusion rate of rituximab, and investigate the safety and feasibility of rapid infusion of rituximab for patients with CD20 positive B-cell lymphomas (CD20+NHL). Patients and Methods. 18 patients with CD20+NHL were registered. This study had six cohort...

Descripción completa

Detalles Bibliográficos
Autores principales: Yokoyama, Masahiro, Terui, Yasuhito, Takeuchi, Kengo, Nara, Eriko, Nakano, Kenji, Ueda, Kyoko, Nishimura, Noriko, Mishima, Yuko, Sakajiri, Sakura, Tsuyama, Naoko, Ozawa, Keiya, Hatake, Kiyohiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2013
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3649348/
https://www.ncbi.nlm.nih.gov/pubmed/23691364
http://dx.doi.org/10.1155/2013/863909

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3649348/
https://www.ncbi.nlm.nih.gov/pubmed/23691364
http://dx.doi.org/10.1155/2013/863909

Ejemplares similares